Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia-Reference-Cited by-同舟云学术

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Published:2022-02 Issue:1 Volume:7 Page:100341
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Cao Y.,Qin S.,Luo S.,Li Z.,Cheng Y.,Fan Y.,Sun Y.,Yin X.,Yuan X.,Li W.,Liu T.,Hsu C.-H.,Lin X.,Kim S.-B.,Kojima T.,Zhang J.,Lee S.-H.,Bai Y.,Muro K.,Doi T.,Bai C.,Gu K.,Pan H.-M.,Bai L.,Yang J.-W.,Cui Y.,Lu W.,Chen J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Randomized phase III keynote-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer;Kojima;J Clin Oncol,2020

3. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial;Kato;Lancet Oncol,2019

4. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study;Huang;Lancet Oncol,2020

5. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma;Daud;J Clin Oncol,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery;Journal of Cardiothoracic Surgery;2024-01-25

2. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study;ESMO Open;2024-01

3. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China;BMJ Open;2023-12

4. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2023-11-23

5. Tumor immune microenvironment remodeling and prognosis of patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy with and without immunotherapy;2023-10-11